scholarly journals Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice

2020 ◽  
Vol Volume 13 ◽  
pp. 4221-4234
Author(s):  
Mario Luca Morieri ◽  
Angelo Avogaro ◽  
Gian Paolo Fadini
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Practice ◽  
Receptor Agonists ◽  
Long Acting

Experience in clinical practice with new long-acting insulins in type 2 diabetes (T2D)

2018 ◽  
Author(s):  
Maria Molina Vega ◽  
Araceli Munoz Garach ◽  
Miguel Damas Fuentes ◽  
Carmen Hernandez Garcia ◽  
Cristina Diaz Perdigones ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Practice ◽  
Long Acting

scholarly journals Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes

Diabetes Care ◽  
2020 ◽  
Vol 43 (9) ◽  
pp. 2137-2145
Author(s):  
Daniel R. Quast ◽  
Nina Schenker ◽  
Björn A. Menge ◽  
Michael A. Nauck ◽  
Christoph Kapitza ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Gastric Function ◽  
Receptor Agonists ◽  
Long Acting

scholarly journals Lixisenatide – A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes

2010 ◽  
Vol 9 (2) ◽  
pp. 76 ◽  
Author(s):  
Josep Vidal ◽  
Keyword(s):  
Type 2 Diabetes ◽  
Glycaemic Control ◽  
Basal Insulin ◽  
Glycated Haemoglobin ◽  
Insulin Analogues ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Long Acting

Optimal glycaemic control is essential to managing risks in patients with type 2 diabetes. However, glycaemic control remains poor among type 2 diabetes patients, particularly the control of post-prandial glucose (PPG). Almost half of patients treated with basal insulin and oral anti-diabetic drugs (OADs) do not achieve their glycated haemoglobin (HbA1c) goals, despite achieving fasting plasma glucose (FPG) control. Glycaemic control targets have emphasised FPG targets, but PPG contributes significantly to overall glycaemic control in type 2 diabetes. Glucagon-like peptide 1 (GLP-1) receptor agonists have shown substantial efficacy in improving overall glycaemic control but have differing effects on PPG, which is a result of their different mechanisms of action. Lixisenatide is unique among existing GLP-1 receptor agonists in that it is short acting but given as a once daily dose, and exerts its main effects during the prandial period. It has demonstrated efficacy in an extensive clinical trial programme. In particular, it has shown a beneficial effect on PPG compared with existing GLP-1 receptor agonists, probably a result of its effect on slowing gastric emptying. This has provided a strong rationale for its use as add-on therapy to long-acting basal insulin analogues, in cases where the latter is not providing adequate glycaemic control. The additive effects on glycaemic control may lead to a new treatment approach to manage blood glucose and prevent long-term complications in patients with type 2 diabetes.

scholarly journals The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea

2015 ◽  
Vol 39 (3) ◽  
pp. 177 ◽  
Author(s):  
Seungjoon Oh ◽  
Suk Chon ◽  
Kyu Jeong Ahn ◽  
In-Kyung Jeong ◽  
Byung-Joon Kim ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Practice ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1
Sign in / Sign up

Export Citation Format

Share Document